Page last updated: 2024-11-04

ly 278584

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

LY 278584: structure given in first source; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3970
CHEMBL ID291046
CHEBI ID91535
SCHEMBL ID9485783
MeSH IDM0170606

Synonyms (34)

Synonym
119193-37-2
1h-indazole-3-carboxamide, 1-methyl-n-(8-methyl-8-azabicyclo(3.2.1)oct-3-yl)-
ly 278584
1-methyl-n-(8-methyl-8-azabicyclo(3.2.1)oct-3-yl)-1h-indazole-3-carboxamide
BRD-A12016240-001-01-7
BPBIO1_000507
LOPAC0_000741
BIOMOL-NT_000163 ,
ly278584
NCGC00162234-02
ly-278,584 maleate
NCGC00162234-01
1-methyl-n-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)indazole-3-carboxamide
CHEMBL291046
CCG-204826
bdbm84739
cas_109216-58-2
nsc_3970
NCGC00015585-02
NCGC00015585-03
SCHEMBL9485783
CHEBI:91535
1-methyl-n-(8-methyl-8-azabicyclo[3.2.1]-oct-3-yl)-1h-indazole-3-carboxamide
DTXSID10922885
1-methyl-n-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1h-indazole-3-carboxamide
Q27163369
1-methyl-n-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-3-indazolecarboxamide
ly-278584; ly278584
BCP33041
1-methyl-n-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]-oct-3-yl]-1h-indazole-3-carboxamide
Z2714240088
AKOS040748814
HY-124117
CS-0084243

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Five-day repeat dosing of a typical SSRI, paroxetine, increased climbing, a distinctive antidepressive behavior, 1 h after but not 1 h before treatment."( Effects of repeated selective serotonin reuptake inhibitor paroxetine treatments on mouse forced swimming.
Akagawa, Y; Hishikawa, Y; Maruyama, A; Masuda, Y; Shimizu, T, 1999
)
0.3
" Rats were acutely dosed with vortioxetine, ondansetron (5-HT3 receptor antagonist) or flesinoxan (5-HT1A receptor agonist)."( Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism.
du Jardin, KG; Jensen, JB; Pehrson, AL; Sanchez, C, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
aromatic amideAn amide in which the amide linkage is bonded directly to an aromatic system.
indazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency2.81840.011212.4002100.0000AID1030
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.03)18.7374
1990's15 (45.45)18.2507
2000's11 (33.33)29.6817
2010's6 (18.18)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.08 (24.57)
Research Supply Index3.58 (2.92)
Research Growth Index5.67 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other35 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]